Navigation Links
Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint

-- Data from Serial Outpatient Infusion Study in Patients with Chronic Decompensated Heart Failure Presented at the American College of Cardiology 56th Annual Scientific Session --

MOUNTAIN VIEW, Calif. and NEW ORLEANS, March 25, 2007 /PRNewswire/ -- Scios Inc. announced today that an exploratory, 920-patient, Phase 2 study of nesiritide (NATRECOR(R)) showed a neutral effect on the primary endpoint, a composite of death and cardiorenal hospitalization at 12 weeks, and provides important renal and mortality safety data on nesiritide in patients with advanced chronic decompensated heart failure (CDHF) receiving serial outpatient infusions.

Data from the study, known as FUSION II (Follow-Up Serial InfusiOns of NATRECOR(R) in Advanced Heart Failure), were presented during a late-breaking clinical trial session at the of Cardiology's 56th Annual Scientific Session in New Orleans (presentation #402-9). Scios also announced that it plans to submit the safety data from this and other recent trials to the U.S. Food and Drug Administration (FDA).

NATRECOR(R) is the only FDA-approved intravenous treatment for patients with acutely decompensated congestive heart failure (ADHF) who have dyspnea (shortness of breath) at rest or with minimal activity.

FUSION II was designed to assess the long-term safety and outcomes at six months of once- or twice-weekly infusions of nesiritide compared to placebo in persistently symptomatic CDHF patients. All patients received ongoing intensive heart failure disease management, including optimization of standard heart failure medications and once or twice weekly outpatient clinic visits. Patients who participated in this trial had to have two prior recent hospitalizations, either NYHA class III or IV heart failure and had to have been out of the hospital for at least five days prior to enrollment in the trial.

The study demonstrated comparable renal and mortality
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/11/2014)... Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) ... Diagnostic Testing Market - Forecasts to 2019: Expected ... and is expected to be valued at USD ... http://photos.prnewswire.com/prnh/20130307/600769 ... segmented according to immunoprotein types which include immunoglobulins, ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... 2014 Yesterday, former Congressman Patrick ... manufacturing facility. Rep. Kennedy and Dick Moberg ... cutting-edge research in neurological disease and treatment. ... advocate, Garen Staglin , created One Mind, ... changes that will radically accelerate the development and ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2
(Date:7/13/2014)... July 13, 2014 Celebrity fitness trainer ... formed a promotional partnership with Aqua Health Labs for ... Omega-3 EPA supplement . The collaboration was recently announced ... fitness trainer , actor, model, and a two ... for A-List celebrities, he has prepared stars including Demi ...
(Date:7/13/2014)... Hope Palliative & Hospice Care announced today ... at the Tamarack Senior Living Community in Palatine, IL. The ... on the 3rd Wednesdays of every month. This group ... Community located at 55 S. Greeley St. Palatine, IL 60067. ... is no cost for the group. , “A grief ...
(Date:7/13/2014)... According to The Peripheral Neuropathy Program review ... that teaches people how to deal with diabetic nerve ... This program also provides people with safe and effective ... including numbness, prickling, burning, and intense stabbing pains. ... treatment program can help people eliminate some types of ...
(Date:7/13/2014)... Recently, iFitDress.com, one of the most popular suppliers of ... a new selection of beautiful evening dresses ... promotion for these evening gowns. Now, everybody can enjoy ... thousands of graceful gowns in its online store. Most ... Italy and many other countries. They are highly appreciated ...
(Date:7/12/2014)... 13, 2014 Recently, Fadhits.com, a well-known wedding ... elegant long graduation dresses to its product line. ... its loyal clients. It wants to bring more benefits for ... now offered at discounted prices, up to 72% off. , ... always working hard. Its online shop is a good place ...
Breaking Medicine News(10 mins):Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:New and Beautiful Evening Dresses Unveiled by iFitDress.com 2Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2
... Life-DaVita Medical Missions, program reaches out to patients in ... need of care ... program is being recognized as life-saving by 16 year-old,Juan Carlos and his ... for survival and was just days away from dying.,This past December, DaVita ...
... studies finds regimen popular in 1980s doesn,t really lengthen ... chemotherapy has only a minimal effect on survival in ... , "It,s pretty clearly established that [high-dose chemotherapy] is ... of the Division of Quantitative Sciences at the University ...
... The fifth annual Gastrointestinal Cancers Symposium is a three-day ... on the latest clinical strategies for the prevention, screening ... are expected to gather at this years Symposium which ... Friday, January 25 Sunday, January 27, 2008, WHERE:, ...
... and Leicester are collaborating in the use of a ... spaces inside the lungs and the results of ... disease and later degenerative lung disease. , There are ... to this particular magnetic resonance technique, which is based ...
... Boston, MAMichael F. Holick, PhD, MD, was recently awarded ... Society of Endocrinology and Metabolism (CSEM). Holick, an ... received the award for decades of pioneering work that ... wide variety of chronic health conditions. , ...
... A clinical study conducted at Henry Ford Hospital on ... patients with the most common and aggressive type of brain ... , The randomized Phase II study focused on patients ... or second-line therapy. The study revealed that more than a ...
Cached Medicine News:Health News:16-Year-Old Ecuadorian Boy in Dire Need of Dialysis Treatments Thanks One of Nation's Leading Providers for Saving His Life 2Health News:16-Year-Old Ecuadorian Boy in Dire Need of Dialysis Treatments Thanks One of Nation's Leading Providers for Saving His Life 3Health News:High-Dose Chemo Provides Little Benefit to Breast Cancer Patients 2Health News:High-Dose Chemo Provides Little Benefit to Breast Cancer Patients 3Health News:New technique reveals insights into lung disease 2Health News:Boston University Medical Center researcher honored 2Health News:Drug study for brain cancer shows promising results 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: